MONEY

Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 16, 2024 - 16:00
Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024
Read More

Tags:

Previous Article

More rivers spill banks in central European floods, death toll rises

Next Article

Jefferies sees Generali stock undervalued amid improved risk profile and profits

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Pricing of Upsized Publ...

Tomas Kauer - Mode... Sep 12, 2024

US stock futures inch lower with CPI data, Harris-Trump debate on tap

US stock futures inch lower with CPI data, Harris-Trump...

Tomas Kauer - Mode... Sep 11, 2024

Maria Elvira Salazar purchases Antero Resources Corporation stock

Maria Elvira Salazar purchases Antero Resources Corpora...

Tomas Kauer - Mode... Sep 13, 2024